Other
Primary Sjögren's Syndrome (pss)
0
Pipeline Programs↗
0
Active Trials↗
2
Companies Involved↗
Primary Sjögren's Syndrome (pSS) is an early-stage landscape with 0 programs across 2 companies. The most active players are GSK, Argenx.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
4
clinical trials
Withdrawn1 · 25%
Completed1 · 25%
Terminated1 · 25%
Unknown status1 · 25%
Clinical Trials
Trial Activity
Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)
Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1/2·NCT00953485·20 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)